Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 9/20 | 0.40 |
| ▸ | ALDH1A2 | O94788 | 8/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845203 | 0.84 | KDM5A (0.42) | ALDH1A1ALOX12PGRKDM5ADPP4 | |
| SCHEMBL22845222 | 0.78 | REN (0.41) | ALDH1A1ALOX12PGRKDM5A | |
| SCHEMBL22845404 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MAPK1HPGDALOX15TSHR | |
| SCHEMBL22717409 | 0.75 | MAPK1 (0.40) | ALDH1A1MAPK1ALOX12PGRKDM5A | |
| SCHEMBL22845268 | 0.71 | ALDH1A1 (0.49) | ALDH1A1LMNATSHRHTT | |
| SCHEMBL22845397 | 0.71 | KDM4E (0.43) | ALDH1A1MAPK1ALOX12PGRKDM5A | |
| SCHEMBL24173442 | 0.70 | SMN1; SMN2 (0.37) | ALDH1A1ALDH1A3ALDH1A2MAPK1LMNA | |
| SCHEMBL22845486 | 0.68 | GNRHR (0.36) | ALDH1A1ALDH1A3MAPK1LMNAHPGD | |
| SCHEMBL22845276 | 0.68 | REN (0.41) | ALDH1A1ALDH1A3ALDH1A2PGR | |
| SCHEMBL22172011 | 0.67 | KDM4C (0.47) | ALDH1A1MAPK1HTTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | ALDH1A1 648/4885ALDH1A3 2482/4885ALDH1A2 1683/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | ALDH1A1 648/4885ALDH1A3 2482/4885ALDH1A2 1683/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | ALDH1A1 648/4885ALDH1A3 2482/4885ALDH1A2 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.